Biotechnology · Boston, Massachusetts, United States
$3.44
-1.15% (-$0.04)2026-07-09
Net Income-$11.8M
EPS$-0.65
Market Cap$64.1M
Price Performance
Historical data including institutional events
Company Profile
R
Robert Connelly
CEO & Executive Director
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers.
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
